Dyadic International, Inc. (NASDAQ: DYAI), operating as Dyadic Applied BioSolutions, has announced definitive agreements with an institutional investor for a registered direct offering and concurrent private placement, aiming to raise approximately $2.9 million in gross proceeds. The offering includes 3,625,000 common shares priced at $0.795 each and warrants to purchase an equal number of shares at an exercise price of $0.84 per share. The warrants are priced at $0.005 each.
The transactions are expected to close on or about August 14, 2026, subject to customary closing conditions. Dyadic intends to use the net proceeds, along with existing cash, cash equivalents, restricted cash, and investment-grade securities, for working capital and general corporate purposes. Aegis Capital Corp. is serving as the exclusive placement agent for the offerings.
This financing comes at a time when the biotechnology sector is increasingly focusing on sustainable and scalable production methods. Dyadic's proprietary Dapibus™ and C1 expression systems are designed to enable rapid, cost-effective, and flexible manufacturing of high-value proteins. These platforms support the growing global demand across life sciences, food and nutrition, and bio-industrial markets, offering an alternative to animal-derived proteins.
The capital raise is likely to bolster Dyadic's efforts in advancing its non-animal protein production platforms. For leaders in the biotech and food industries, this move underscores the continued investor interest in sustainable protein technologies. The funds will enable Dyadic to further develop its technologies and potentially expand its customer base, which could accelerate the adoption of animal-free proteins in various applications.
According to the company, the offering is part of a broader strategy to strengthen its financial position and support its growth initiatives. The ability to secure financing from institutional investors reflects confidence in Dyadic's technological approach and market potential. As the demand for sustainable protein sources rises, companies like Dyadic are positioned to play a pivotal role in transforming how proteins are produced for both medical and nutritional uses.
The news of this offering may have implications for the industry, as it signals continued investment in biotech solutions that address sustainability challenges. For businesses operating in the life sciences and food sectors, monitoring such developments is crucial, as they could influence supply chains and product development strategies. Dyadic's progress could also impact the competitive landscape, as more players seek to capitalize on the shift toward non-animal proteins.
For more details on the offering, the full press release is available at https://ibn.fm/od7FJ. Information about Dyadic International and its technologies can be found on their website at https://dyadic.com/.
